Breast Inflammatory Carcinoma — Variants & evidence

Breast Inflammatory Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

2 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MMP2 SERUM LEVELS1
Bevacizumab	Predictive	B	Supports Sensitivity Response	3	accepted	EID1156 MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Hig… (full text at CIViC) PMID 26921265 · Tabouret et al., 2016 · Open in CIViC	civic
MMP9 SERUM LEVELS1
Bevacizumab	Predictive	B	Supports Resistance	3	accepted	EID1157 MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low… (full text at CIViC) PMID 26921265 · Tabouret et al., 2016 · Open in CIViC	civic

Data updated 22 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.